DENIM is an abbreviation of “Dendritic cell Immunotherapy for Mesothelioma”. Malignant pleural mesothelioma is a rare but highly aggressive cancer that kills about 43,000 people worldwide every year. Unfortunately, there is no therapy for mesothelioma, which makes it a highly fatal disease. Thus, there is a clear unmet medical need on the treatment of mesothelioma. The main objective of the project is to demonstrate the efficacy of dendritic cell-based immunotherapy in a randomised phase II/III clinical trial, to address this urgent need. This could potentially lead to a cure of asbestos-exposed workers, consumers and people with cancer. This project runs from 2016 until 2019.
ECPC’s Role
The European Cancer Patient Coalition ensures the project’s compliance with the needs of the people with cancer and is involved in the work package responsible for the effective dissemination of the project news and results among external stakeholders. ECPC also shares news and results related to the project to all its Members through the monthly newsletter, the website and social media platforms.
Contact Points
ECPC: Klevisa Ceka, ECPC Head of Health and Research Programmes
Principal Investigator: Prof. dr. Joachim Aerts, Erasmus Medical Centre
Funding
This project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 668769
Project Website
